IGFBP-3: When to Order This Test

The direct answer

IGFBP-3 is ordered to support, not replace, a GH-axis workup that starts with IGF-1. In children with short stature, in adults with known pituitary disease, and in patients being monitored on growth hormone therapy, the combination of IGF-1 and IGFBP-3 gives more diagnostic information than either test alone, and the 2011 Endocrine Society adult GH deficiency guideline recommends measuring both as part of the initial biochemical evaluation (Molitch et al. 2011). The useful clinical question is rarely "is IGFBP-3 high or low" in isolation. It is whether IGFBP-3 agrees with IGF-1, because when the two disagree, that disagreement usually points toward a specific confounder, malnutrition, oral estrogen, liver disease, or renal impairment, rather than toward the GH axis itself.

What IGFBP-3 actually measures

IGFBP-3 is the dominant carrier protein for IGF-1 and IGF-2 in serum. It forms a large ternary complex with an acid-labile subunit that extends the circulating half-life of IGF-1 well beyond its unbound half-life of roughly 10 minutes (Baxter 2013). The liver produces most circulating IGFBP-3 under growth hormone stimulation, acting through the GH receptor-JAK2-STAT5 pathway.

Because IGFBP-3 production depends on integrated GH secretion over roughly 24 hours, a single blood draw can serve as a proxy for overall GH activity without the serial overnight sampling that direct GH stimulation testing requires. IGFBP-3 also has GH-independent roles, it can inhibit cell proliferation and promote apoptosis through nuclear receptor interactions, which is why it appears separately in oncology research (Baxter 2014). That oncology literature is background for understanding the protein's biology; it does not change how the test is used in a GH-axis workup.

When clinicians order it

Pediatric short stature evaluation. This is the most common reason for the test. When a child's height falls well below population norms or growth velocity is persistently slow, IGF-1 and IGFBP-3 are typically drawn before proceeding to provocative GH stimulation testing (Grimberg et al. 2016). Low IGF-1 combined with low IGFBP-3 raises the pretest likelihood of GH deficiency substantially when clinical suspicion is already high, though the exact predictive value depends on the population tested and should be confirmed against the current guideline text rather than treated as a fixed number.

Adult GH deficiency screening. Adults with a history of pituitary surgery, radiation, traumatic brain injury, or an empty sella need GH axis assessment. The Endocrine Society lists IGFBP-3 as an adjunct to IGF-1, most useful when IGF-1 sits in an equivocal low-normal range (Molitch et al. 2011).

Monitoring GH replacement therapy. IGFBP-3 rises alongside IGF-1 once recombinant GH is started. AACE guidance supports periodic monitoring of both markers during dose titration, with IGF-1 generally carrying more weight in dosing decisions and IGFBP-3 used as a secondary check (Cook et al. 2009; Yuen et al. 2019).

Suspected acromegaly or gigantism. IGF-1 is the primary screening test for GH excess. Elevated IGFBP-3 can support the diagnosis but is confirmatory rather than the lead test; the oral glucose tolerance test with nadir GH remains the diagnostic gold standard (Katznelson et al. 2014).

Nutritional context. When IGF-1 is low but malnutrition, chronic liver disease, or critical illness could explain the suppression on its own, a preserved IGFBP-3 argues against true GH deficiency, because IGFBP-3's longer half-life and ternary-complex stability buffer it against short-term metabolic stress compared with IGF-1 (Counts et al. 1992).

Normal ranges by age, and their limits

Reference intervals shift across the lifespan, generally rising through childhood, peaking during puberty, and declining slowly thereafter (Blum et al. 2018). Typical adult ranges cluster around 3.5-7.0 mg/L, with lower values common in older adults. These figures are illustrative, not exact cutoffs to self-diagnose against: IGFBP-3 assays are not standardized across manufacturers, and Quest Diagnostics and LabCorp, among others, use different antibody pairs and calibrators. Always interpret a result against the reference interval printed on that specific lab report, not against numbers quoted online.

How IGFBP-3 differs from IGF-1

Both markers track GH activity, but they behave differently under physiologic stress. IGF-1 falls more sharply than IGFBP-3 during acute critical illness, a pattern discussed in reviews of the GH-IGF axis in critically ill patients (Teng Chung & Hinds 2006); exact percentage drops vary by study population and should not be quoted as a fixed figure without checking the primary study.

IGF-1 also falls with oral estrogen use, oral contraceptives and oral hormone therapy suppress IGF-1 through first-pass hepatic effects, while IGFBP-3 is comparatively more stable (Leung et al. 2004). This dissociation can create a false impression of GH deficiency if only IGF-1 is checked in a woman on oral estrogen.

The pairing is often most informative as a ratio rather than as two separate numbers. A markedly low IGF-1 relative to IGFBP-3 is a pattern described in GH insensitivity (Laron syndrome), where GH signaling itself is defective rather than GH secretion (Savage et al. 2010). Specific numeric cutoffs for this ratio vary across the literature and should be confirmed with an endocrinologist rather than applied mechanically.

What high IGFBP-3 means

Elevated IGFBP-3, above the age-adjusted normal range, occurs in three main settings.

GH excess. Acromegaly and gigantism raise GH secretion, which upregulates hepatic IGFBP-3. Elevated IGFBP-3 alongside elevated IGF-1 supports this diagnosis but does not replace confirmatory testing (Katznelson et al. 2014).

Exogenous GH use. Supraphysiologic GH administration, including non-medical use, raises IGFBP-3. Anti-doping programs use the GH-IGF-1-IGFBP-3 axis as part of detection strategies (Holt & Sönksen 2008).

Reduced renal clearance. Chronic kidney disease can raise IGFBP-3 independent of GH status because the kidney contributes to its clearance (Tönshoff et al. 1997). The magnitude of this effect varies by CKD stage and should not be assumed to follow a fixed percentage.

Isolated IGFBP-3 elevation without a corresponding IGF-1 rise is unusual. When it occurs, check renal function and consider assay interference, including heterophilic antibodies or high-dose biotin supplementation.

What low IGFBP-3 means

Low IGFBP-3, below the age-adjusted normal range, signals reduced GH action at the liver, but the cause is not always the GH axis itself.

GH deficiency. Congenital GH deficiency and acquired GH deficiency from pituitary surgery, irradiation, or infiltrative disease all suppress IGFBP-3.

GH insensitivity (Laron syndrome). The GH receptor is dysfunctional, so GH levels may be normal or high while IGFBP-3 production cannot proceed normally (Rosenfeld et al. 1994). Specific numeric ranges reported for this condition vary by cohort and assay era; treat any single figure as illustrative rather than diagnostic.

Severe hepatic dysfunction. Because the liver is the primary production site, advanced cirrhosis or acute liver failure can reduce IGFBP-3 independent of the GH axis (Donaghy et al. 1997).

Prolonged malnutrition. Sustained protein-calorie malnutrition eventually suppresses IGFBP-3, though this generally requires a more sustained insult than what is needed to suppress IGF-1 (Counts et al. 1992).

Poorly controlled type 1 diabetes. Portal insulin deficiency reduces hepatic GH receptor expression, which can lower IGFBP-3 synthesis, with degree of suppression tracking glycemic control in at least one adolescent cohort study (Bereket et al. 1999). The exact magnitude reported in that study should be verified against the original paper before being quoted as a general rule.

Can you raise or lower IGFBP-3 directly?

No supplement or lifestyle change raises or lowers IGFBP-3 independent of its underlying driver. Every legitimate approach works by correcting the cause.

To raise it: confirmed GH deficiency is treated with recombinant human GH under endocrinology supervision, with IGF-1 as the primary dose-titration target and IGFBP-3 tracked as a secondary marker (Molitch et al. 2011). Nutritional repletion in malnourished patients and improved glycemic control in type 1 diabetes can partially restore IGFBP-3 over weeks to months. Sleep restriction studies show that severely curtailed sleep reduces GH-axis markers including IGF-1 (Spiegel et al. 1999); the corollary, that consistent adequate sleep supports normal GH pulsatility, is physiologically plausible but is not the same as a proven intervention to raise IGFBP-3 in a specific patient.

To lower it: this is rarely a goal on its own. When IGFBP-3 is elevated because of GH excess, treatment targets the adenoma: transsphenoidal surgery, somatostatin analogs such as octreotide or lanreotide, the GH receptor antagonist pegvisomant, or radiation therapy, each of which lowers GH-axis markers as a downstream effect of controlling the underlying disease (Katznelson et al. 2014; Caron et al. 2014; van der Lely et al. 2001). Reported normalization rates vary by treatment, patient population, and follow-up duration in these trials; consult the primary papers rather than a single quoted percentage when counseling a specific patient.

Observational data have linked higher IGFBP-3 and IGF-1 levels within the general population to some cancer risks, including premenopausal breast cancer, but no intervention trial has tested whether deliberately lowering IGFBP-3 within a normal range changes cancer outcomes (Renehan et al. 2004). This is an association from observational epidemiology, not an established causal or actionable target.

Ordering logistics

IGFBP-3 requires a standard serum tube and no fasting, because it lacks the diurnal variation that direct GH measurement has. High-dose biotin supplementation can interfere with some immunoassay platforms, producing falsely low or falsely high results depending on the assay design, so patients are generally advised to stop biotin for a few days before the draw and to tell the lab if they take it regularly (Li et al. 2017). Serum IGFBP-3 is reasonably stable under refrigeration for send-out testing.

Out-of-pocket cost and insurance coverage for IGFBP-3 vary by lab, insurer, and diagnosis code, and change over time; a reader should confirm current pricing and coverage directly with their lab and insurer rather than relying on a fixed number from an article.

Evidence boundary: what is established, what is not

Established: IGFBP-3 is GH-dependent, produced mainly in the liver, and is the standard companion test to IGF-1 in evaluating suspected GH deficiency or excess, per Endocrine Society and AACE guidance. It is generally more stable than IGF-1 during acute illness, malnutrition, and oral estrogen use.

Plausible but not rigorously quantified for an individual patient: specific percentage drops during critical illness, specific normalization rates after acromegaly treatment, and specific ratio cutoffs for GH insensitivity all appear in the literature but vary by study population, assay, and era. These numbers are useful for understanding direction and rough magnitude, not for precise individual risk calculation.

Not established: that any supplement, diet, or over-the-counter intervention meaningfully raises or lowers IGFBP-3 independent of treating its underlying driver. That lowering IGFBP-3 in the normal range changes cancer risk. Isolated IGFBP-3 results without IGF-1 and clinical context should not be used to diagnose or exclude a GH-axis disorder.

Decision framework: interpreting IGF-1 and IGFBP-3 together

Exceptions that change the pathway: a normal IGF-1 does not rule out adult GH deficiency, since the sensitivity of IGF-1 alone is limited depending on age, sex, and BMI (Molitch et al. 2011); in that gray zone, IGFBP-3 and clinical suspicion both matter more than either lab value alone. In patients already stable on GH replacement, IGF-1 alone is often sufficient for routine dose checks, and IGFBP-3 is reserved for cases where IGF-1 is ambiguous.

When to seek urgent care rather than wait for lab interpretation: new visual field loss, severe headache with vomiting, or signs of pituitary apoplexy warrant emergency evaluation regardless of pending IGFBP-3 or IGF-1 results.

Common questions